Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been approved for treating advanced ovarian cancer associated with defective BRCA genes, the Food and Drug Administration announced on...
Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been approved for treating advanced ovarian cancer associated with defective BRCA genes, the Food and Drug Administration announced on...
The total number of abortions, the rate of abortions per 1,000 women, and the ratio of abortions to live births all reached historic lows in 2011, according to a study published in Morbidity and...
Adult women with no regular health care provider or no health insurance were much less likely to have been screened for cervical cancer in the past 5 years, a study from the Centers for Disease...
Adult women with no regular health care provider or no health insurance were much less likely to have been screened for cervical cancer in the past 5 years, a study from the Centers for Disease...
Both male and female veterans were more likely to have arthritis than were nonveterans, according to a study from the Centers for Disease Control and Prevention.
For male veterans, the...
SILVER SPRING, MD. – The majority of a Food and Drug Administration advisory panel agreed that the risk-benefit profile of panobinostat as add-on treatment to bortezomib and dexamethasone did not...
Close to 8 million women aged 21-65 years were not screened for cervical cancer in the past 5 years even though the disease claims nearly 4,000 lives per year, according to 2012 data, the Centers for...
Close to 8 million women aged 21-65 years were not screened for cervical cancer in the past 5 years even though the disease claims nearly 4,000 lives per year, according to 2012 data, the Centers for...
The first combination pill to treat chronic hepatitis C virus genotype 1 infection was approved by the Food and Drug Administration Oct. 10.
The once-daily tablet under the trade name Harvoni...